Trauma Clinical Trial
Official title:
Effect of Immediate, Pre-emptive Fibrinogen Concentrate in Patients With Trauma Haemorrhage Needing Haemostatic Resuscitation - a Randomized, Controlled, Double-blinded Investigator-initiated Pilot Trial
Effect of immediate, pre-emptive fibrinogen concentrate in patients with trauma haemorrhage needing haemostatic resuscitation - a randomized, controlled, double-blinded investigator-initiated pilot trial
Objective To assess the efficacy and safety of an immediate pre-emptive first-line treatment
with fibrinogen concentrate in patients with trauma haemorrhage in need of haemostatic
resuscitation.
Hypothesis Immediate, pre-emptive first-line treatment of fibrinogen concentrate in trauma
patients with ongoing critical haemorrhage will increase the clot strength.
Background Trauma haemorrhage remains a leading cause of morbidity and mortality. Fibrinogen
is an essential endogenous component of haemostasis and the plasma level is associated to
bleeding, transfusion and outcome.
Trial rationale Fibrinogen concentrate is widely used to correct acquired
hypofibrinogenaemia, recommended by several international guidelines including in trauma,
but evidence is lacking regarding the treatment safety and efficacy.
Trial population The trial population are patients' ≥ 18 years admitted to the Trauma Centre
at Rigshospitalet with immediate need for blood transfusion at arrival and an expected need
for haemostatic resuscitation with multiple transfusions during the initial resuscitation.
Estimated 30-day mortality is 20 % in the population. Patients included in the trial will be
temporarily incompetent because of acute, severe illness related to the ongoing critical
bleeding needing multiple transfusion and immediate intervention to control bleeding.
Trial design This is a single centre, randomized (1:1, active:placebo), placebo controlled,
double-blind investigator-initiated phase II trial in patients with traumatic, critical
bleeding, investigating the safety and efficacy of immediate and pre-emptive administration
of fibrinogen concentrate (Riastap®) or placebo as i.v infusion in 40 patients. All patients
will receive standard of care including damage control surgery, radiological interventions
and haemostatic resuscitation as part of their treatment at Rigshospitalet.
Patients considered to be included in the trial will be temporarily incompetent because of
the acute, critical bleeding related to trauma, so scientific guardians will co-sign the
informed consent form. Next-of-kin and the patients' general practitioner or the patients
will co-sign as soon as possible.
During the study blood samples will be taken at different time points. Patients will be
observed and assessed continuously throughout the first 72 hours. During the extended follow
up period at day 30, contact will be made with the patients to follow up on safety events
and establish potential mortality.
Investigational product Immediate intravenous administration as a single dose of fibrinogen
concentrate (Riastap®, CSL Behring), when haemostatic resuscitation is deemed necessary by
the clinician. The aim is to give the intervention < 1 hour of arrival, and the intervention
should, when possible, be given prior to blood products.
Placebo and blinding Saline 0.9% will be used as placebo. The volume of placebo to be
administered is equal to the volume active drug administered. The content (Riastap® or
placebo) will be provided in opaque syringes and infusion sets (yellow-coloured) to disguise
the content of the allocation to the treatment team.
Outcome measures
Primary outcome measure:
• Thrombelastograph (TEG®) Functional Fibrinogen (FF) maximum amplitude (MA) in mm at 15 min
post intervention
Secondary outcome measures:
- TEG® FF MA in mm at 2, 6, 24 and 72 hours post intervention
- TEG® MA in mm at 15 min., 2, 6, 24 and 72 hours post intervention
- Transfusion requirements (Red blood cells (RBC) or fresh frozen plasma (FFP) or
platelets (PLT)) at 2, 6, 24, 72 hours and in total at day 30
- Total use of haemostatic therapy (i.e. use of coagulation factor concentrates and
tranexamic acid) in the first 24 and 72 hours, omitted from this is active treatment
(intervention)
- Time to intervention or placebo
- Time to FFP and PLT transfusion
- Percentage of patients receiving intervention or placebo < 1 hour of arrival
- Time to surgical control of bleeding as noted by the surgeon
- Severe adverse reactions at day 30, defined as symptomatic thromboembolism at day 30
and anaphylaxis at day 30
- 24-hour and 30-day mortality
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04848376 -
Post-Market Clinical Follow-up Study of A-SPINE's Products
|
||
Terminated |
NCT03781817 -
Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children With Non-operative Fractures
|
Phase 4 | |
Completed |
NCT04342416 -
Using a Brief Visuospatial Interference Intervention to Reduce Intrusive Memories Among Trauma Exposed Women
|
N/A | |
Recruiting |
NCT04856449 -
DBT Skills Plus EMDR for BPD and Trauma
|
N/A | |
Completed |
NCT04356963 -
Adjunct VR Pain Management in Acute Brain Injury
|
N/A | |
Completed |
NCT05669313 -
The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM
|
||
Active, not recruiting |
NCT03622632 -
Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
|
||
Recruiting |
NCT04725721 -
Testing FIRST in Youth Outpatient Psychotherapy
|
N/A | |
Active, not recruiting |
NCT05530642 -
An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Not yet recruiting |
NCT03696563 -
FreeO2 PreHospital - Automated Oxygen Titration vs Manual Titration According to the BLS-PCS
|
N/A | |
Withdrawn |
NCT03249129 -
Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma
|
||
Completed |
NCT02240732 -
Surgical Tourniquets and Cerebral Emboli
|
N/A | |
Completed |
NCT02227979 -
Effects of PURPLE Cry Intervention
|
N/A | |
Withdrawn |
NCT01169025 -
Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients
|
N/A | |
Recruiting |
NCT01812941 -
Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients
|
N/A | |
Completed |
NCT01475344 -
Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC)
|
Phase 1/Phase 2 | |
Completed |
NCT03112304 -
Child STEPS for Youth Mental Health in Maine Sustainability
|
N/A | |
Completed |
NCT01210417 -
Trauma Heart to Arm Time
|
N/A | |
Completed |
NCT01201863 -
Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy
|
Phase 4 |